Dot1L-IN-4 | DOT1L Inhibitor

Cas No.:
Chemical Name:	Dot1L-IN-4
Synonyms:	Dot1L-IN-4;BDBM50529550;N4Z
SMILES:	ClC1C([H])=C([H])C([H])=NC=1[C@]([H])(C1C([H])=C([H])C([H])=C2C=1OC(O2)(F)F)N([H])C1C([H])=C([H])C(=C([H])C=1N([H])C1N=C(N=C(N=1)N1C([H])([H])C([H])([H])N([H])C([H])([H])C1([H])[H])OC([H])([H])[H])S(C([H])([H])[H])(=O)=O
Formula:	C₂₈H₂₇ClF₂N₈O₅S
M.Wt:	661.0794
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

COA

Cat. No.	Product name	Field of application
DC47618	PRMT5-IN-10	PRMT5-IN-10 has promising structure-dependent inhibition of the protein methyltransferase PRMT5:MEP50 complex.
DC47617	EED ligand 1	EED ligand 1 is a diverse, potent, and efficacious inhibitor that target the EED subunit of the polycomb repressive complex 2 (PRC2) methyltransferase.
DC47615	PRMT5-IN-9	PRMT5-IN-9 is a novel PRMT5 inhibitor for treating cancer, with an IC50 of 0.01 μM.
DC47613	PRMT5-IN-12	PRMT5-IN-12 shows remarkable inhibitory activity on PRMT5.
DC47612	PRMT5-IN-11	PRMT5-IN-11 is a promising structure-dependent inhibition of the protein methyltransferase PRMT5:MEP50 complex in the (sub)micromolar range.
DC47611	PRMT5-IN-14	PRMT5-IN-14 is a PRMT5 inhibitor to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
DC47610	PRMT5-IN-3	PRMT5-IN-3 is a PRMT5 inhibitor that exhibits synthetic lethality to tumor cells but produce few side effects combined with DNA damaging agents.
DC47609	PRMT1-IN-1	PRMT1-IN-1 is a PRMT1 inhibitor.
DC47264	MS67	MS67 is a potent and selective WD40 repeat domain protein 5 (WDR5) degrader with a Kd of 63 nM. MS67 is inactive against other protein methyltransferases, kinases, GPCRs, ion channels, and transporters. MS67 shows potent acticancer effects.
DC47262	MRTX9768 hydrochloride	MRTX9768 hydrochloride is a potent, orally active PRMT5 inhibitor. MRTX9768 hydrochloride is a synthetic lethal-based inhibitor binding the PRMT5-MTA complex.